SPCs: extending protection lifespan
Two references to the Court of Justice of the European Union should help clarify the position on what exactly is eligible for a supplementary protection certificate, as Michael Pears and Joel Beevers of Potter Clarkson explain.
Latest news
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
20-08-2019
Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
50 Key Influencers In The Life Sciences
- LSIPR 50 2018: Robert Nelsen 05-09-2018
- LSIPR 50 2018: Stephen Knight 04-09-2018
Regions
- Fed Circuit majority ‘problematically’ adds new rule in Actavis suit: chief judge
- Allergan says rivals using trade secrets disclosed by USITC order
- Sanofi victorious at Fed Circ in prostate cancer drug dispute
- Pharma bodies sign NDAs with UK govt over no-deal Brexit plans
- Fed Circ affirms Eli Lilly victories over cancer drugs